Brief: Seelos Therapeutics Announces Encouraging Data From An In Vivo Study Of Sls-005 In An Aggressive Preclinical Model Of Alzheimer's Disease
27/09/2023 13:05
Sept 27 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES ENCOURAGING DATA FROM AN IN
VIVO
STUDY OF SLS-005 IN AN AGGRESSIVE PRECLINICAL MODEL OF
ALZHEIMER'S DISEASE
* SEELOS THERAPEUTICS - TREATMENT WITH SLS-005 SHOWED 46%
REDUCTION IN TAU PROTEIN,18% REDUCTION IN NFL BIOMARKER FROM
BASELINE VALUES WITHIN SIX MONTHS
* SEELOS THERAPEUTICS INC - TOP-LINE DATA FROM SLS-005
REGISTRATIONAL PHASE II/III TRIAL IN ALS EXPECTED TO BE RELEASED
IN Q4 OF 2023
Source text for Eikon: ID:nPn2jWVZRa
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio